TME PHARM.CONF.IPO EO 1- (0N6A) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.92x
TME PHARM.CONF.IPO EO 1- (0N6A) has a Cash Flow-to-Debt Ratio of -0.92x as of December 2025, meaning its operating cash flow of €-3.42 Million could theoretically repay -1% of its total liabilities (€3.72 Million) in one year. See 0N6A financial flexibility score to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.92x
Operating CF / Total Liabilities
Operating Cash Flow
€-3.42 Million
EUR
Total Liabilities
€3.72 Million
EUR
Data as of
Dec 2025
Most recent filing
TME PHARM.CONF.IPO EO 1- Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for TME PHARM.CONF.IPO EO 1- across 5 annual periods. For the full cash flow conversion analysis, see how efficiently does TME PHARM.CONF.IPO EO 1- generate cash.
Annual Cash Flow-to-Debt Ratio for TME PHARM.CONF.IPO EO 1- (2021–2025)
Year-by-year debt coverage analysis for TME PHARM.CONF.IPO EO 1-.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.92x | €-3.42 Million | €3.72 Million | ▲ +64.4% |
| 2024 | -2.59x | €-4.63 Million | €1.79 Million | ▼ -27.8% |
| 2023 | -2.02x | €-5.63 Million | €2.79 Million | ▼ -8.5% |
| 2022 | -1.86x | €-12.14 Million | €6.51 Million | ▲ +20.7% |
| 2021 | -2.35x | €-12.38 Million | €5.27 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.